Maple Medical Co., Ltd.

Announcement on Extension of Assessment Report for This Transaction

Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. Plans to Issue Shares and Pay Cash for Asset Acquisition Valuation Report

Summary of Draft Report on Share Issuance and Cash Payment for Asset Acquisition by Guangzhou Maipu Regenerative Medicine Technology Co., Ltd.

Draft Report on Share Issuance and Cash Payment for Asset Acquisition and Related Transactions by Guangzhou Maipu Regenerative Medicine Technology Co., Ltd.

Independent Financial Advisor Report on Asset Acquisition and Fundraising by Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (Revised)

Announcement on Revised Draft Report for Share Issuance and Cash Payment for Asset Acquisition and Related Transactions

Review Opinions from the 10th Meeting of the Independent Directors of the 3rd Board

Announcement of Resolutions from the 21st Meeting of the 3rd Board of Directors

Announcement on the Implementation of the 2025 Annual Equity Distribution

Legal Opinion on the 2025 Annual Shareholders' Meeting of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd.

Announcement of Resolutions of the 2025 Annual Shareholders' Meeting

Announcement on Holding the 2025 Online Performance Briefing

Pre-disclosure Announcement on Shareholder Reduction of Shares Before the Company's Initial Public Offering

Announcement on receiving the notice from the Shenzhen Stock Exchange regarding the resumption of review for issuing shares to purchase assets and raising supporting funds and related transactions

Announcement on the Reappointment of the Accounting Firm for 2026

2025 Annual Work Report of the Board of Directors

Announcement on Confirming the Compensation of Directors and Senior Management for 2025 and Formulating the Compensation Plan for 2026

2025 Annual Report of Independent Directors (Chen Jianhua, current)

2025 Annual Report of Independent Directors (Chen Xiaoming, current)

2025 Annual Report of Independent Directors (Yuan Qing, resigned)

2025 Annual Report of Independent Directors (Yuan Ruobin, current)

Internal Control Audit Report

Internal Control Evaluation Report for the Year 2025

Compensation Management System for Directors and Senior Management (April 2026)

Internal Review System for Information Release and Responses on the Interactive Platform (April 2026)

Announcement on Changes in Accounting Policies

Announcement on the Progress of Signing Supplementary Agreements and Related Transactions

Announcement on Estimated Routine Related Transactions for 2026

Notice of the 2025 Annual Shareholders' Meeting

Announcement of Resolutions from the 18th Meeting of the 3rd Board of Directors

Announcement on the Profit Distribution Plan for the Year 2025

2026 First Quarter Report

2025 Special Report on Securities and Derivatives Investment Situation

Report on the Evaluation of the Accounting Firm's Performance in 2025 and the Audit Committee's Fulfillment of Supervisory Responsibilities

Special Audit Explanation on Non-Operating Fund Occupation and Other Related Fund Transactions

2025 Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions

Board's Special Opinion on the Independence Assessment of Independent Directors

2025 Annual Audit Report

2025 Annual Report

2025 Annual Report Summary

Supplementary Legal Opinion from Beijing Zhonglun Law Firm Regarding the Issuance of Shares and Cash Payment for Asset Acquisition and Fundraising and Related Transactions of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (II)

Independent Financial Advisor Report from Huatai United Securities Co., Ltd. Regarding the Issuance of Shares and Cash Payment for Asset Acquisition and Fundraising and Related Transactions of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (Revised)

Review Report on the Consolidated Financial Statements

Summary of the Draft Report on Issuing Shares and Paying Cash for Asset Acquisition and Fundraising and Related Transactions of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (Revised)

Draft Report on Issuing Shares and Paying Cash for Asset Acquisition and Fundraising and Related Transactions of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (Revised)

Supplementary Legal Opinion from Beijing Zhonglun Law Firm Regarding the Issuance of Shares and Cash Payment for Asset Acquisition and Fundraising and Related Transactions of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (I) (Revised)

Special Verification Opinion from Huatai United Securities Co., Ltd. Regarding the Response to the Inquiry Letter on Issuing Shares and Paying Cash for Asset Acquisition and Fundraising Application from Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (Revised)

Special Verification Opinion from Huaxing Accounting Firm (Special General Partnership) Regarding the Response to the Inquiry Letter on Issuing Shares and Paying Cash for Asset Acquisition and Fundraising Application from Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (Revised)

Response from Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. to the Shenzhen Stock Exchange's Inquiry Letter Regarding the Issuance of Shares and Cash Payment for Asset Acquisition and Fundraising Application

Announcement on the Revision of the Draft Report on Issuing Shares and Paying Cash for Asset Acquisition and Fundraising and Related Transactions

Audit Report of Guangzhou Yijie Medical Technology Co., Ltd.

Response to Asset Evaluation Related Issues in the Review Inquiry Letter from Guangdong Lianxin Asset Evaluation Land Real Estate Valuation Co., Ltd. Regarding Guangzhou Maipu Regenerative Medicine Technology Co., Ltd.'s Issuance of Shares and Cash Payment for Asset Acquisition and Fundraising Application (Revised)

Review Opinion from the 9th Meeting of the Special Meeting of Independent Directors of the 3rd Board of Directors

Announcement of the 19th Meeting Resolutions of the 3rd Board of Directors

Announcement on the pledge of shares by company shareholders

Announcement on the Company's Products Entering the Special Review Procedure for Innovative Medical Devices

Announcement on the Expiration of Shareholding Reduction Period for Shareholders Holding More Than 5%

Indicative Announcement on Changes in Equity of Shareholders Holding 5% or More of Shares

Simplified Report on Changes in Equity (Fengyan Fund)

Announcement on the Pledge of Shares by the Company's Actual Controller and Controlling Shareholder